MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The Senate has voted to confirm the nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Publicly traded ...

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

It will compare the shot against a ... to a current vaccine due to start shortly. Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property ...

For comparison, Pfizer reported yesterday that Abrysvo made ... try to stay ahead of other potential competitors, including Moderna and Bavarian Nordic. Meanwhile, the rivalry between the two ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

Infected sea urchin on Reunion Island. Photo credit: Jean-Pascal Quod.

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer a yield above 6%. Which of these two high-yield dividend payers is ...

This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither ...

The health sector had 21 companies reporting their quarterly earnings this week, with 18 of them beating profit estimates for the quarter. Quarter-To-Date, The Health Care Select Sector SPDR Fund ETF ...